201 related articles for article (PubMed ID: 27472081)
1. Prevention of Proliferative Vitreoretinopathy by Suppression of Phosphatidylinositol 5-Phosphate 4-Kinases.
Ma G; Duan Y; Huang X; Qian CX; Chee Y; Mukai S; Cui J; Samad A; Matsubara JA; Kazlauskas A; D'Amore PA; Gu S; Lei H
Invest Ophthalmol Vis Sci; 2016 Jul; 57(8):3935-43. PubMed ID: 27472081
[TBL] [Abstract][Full Text] [Related]
2. A potential role for PDGF-C in experimental and clinical proliferative vitreoretinopathy.
Lei H; Hovland P; Velez G; Haran A; Gilbertson D; Hirose T; Kazlauskas A
Invest Ophthalmol Vis Sci; 2007 May; 48(5):2335-42. PubMed ID: 17460299
[TBL] [Abstract][Full Text] [Related]
3. Assessment of the integrin alpha5beta1 antagonist JSM6427 in proliferative vitreoretinopathy using in vitro assays and a rabbit model of retinal detachment.
Zahn G; Volk K; Lewis GP; Vossmeyer D; Stragies R; Heier JS; Daniel PE; Adamis AP; Chapin EA; Fisher SK; Holz FG; Löffler KU; Knolle J
Invest Ophthalmol Vis Sci; 2010 Feb; 51(2):1028-35. PubMed ID: 19815730
[TBL] [Abstract][Full Text] [Related]
4. Vitreous M2 Macrophage-Derived Microparticles Promote RPE Cell Proliferation and Migration in Traumatic Proliferative Vitreoretinopathy.
Song Y; Liao M; Zhao X; Han H; Dong X; Wang X; Du M; Yan H
Invest Ophthalmol Vis Sci; 2021 Sep; 62(12):26. PubMed ID: 34554178
[TBL] [Abstract][Full Text] [Related]
5. Introduction of the MDM2 T309G Mutation in Primary Human Retinal Epithelial Cells Enhances Experimental Proliferative Vitreoretinopathy.
Zhou G; Duan Y; Ma G; Wu W; Hu Z; Chen N; Chee Y; Cui J; Samad A; Matsubara JA; Mukai S; D'Amore PA; Lei H
Invest Ophthalmol Vis Sci; 2017 Oct; 58(12):5361-5367. PubMed ID: 29049737
[TBL] [Abstract][Full Text] [Related]
6. Overexpression p21WAF1/CIP1 in suppressing retinal pigment epithelial cells and progression of proliferative vitreoretinopathy via inhibition CDK2 and cyclin E.
Wang Y; Yuan Z; You C; Han J; Li H; Zhang Z; Yan H
BMC Ophthalmol; 2014 Nov; 14():144. PubMed ID: 25421815
[TBL] [Abstract][Full Text] [Related]
7. Targeting of integrin-linked kinase with a small interfering RNA suppresses progression of experimental proliferative vitreoretinopathy.
Guo L; Yu W; Li X; Zhao G; Liang J; He P; Wang K; Zhou P; Jiang Y; Zhao M
Exp Eye Res; 2008 Dec; 87(6):551-60. PubMed ID: 18926819
[TBL] [Abstract][Full Text] [Related]
8. BMP7 antagonizes proliferative vitreoretinopathy through retinal pigment epithelial fibrosis in vivo and in vitro.
Yao H; Ge T; Zhang Y; Li M; Yang S; Li H; Wang F
FASEB J; 2019 Mar; 33(3):3212-3224. PubMed ID: 30383450
[TBL] [Abstract][Full Text] [Related]
9. The role of thrombin in proliferative vitreoretinopathy.
Bastiaans J; van Meurs JC; Mulder VC; Nagtzaam NM; Smits-te Nijenhuis M; Dufour-van den Goorbergh DC; van Hagen PM; Hooijkaas H; Dik WA
Invest Ophthalmol Vis Sci; 2014 Jul; 55(7):4659-66. PubMed ID: 25015355
[TBL] [Abstract][Full Text] [Related]
10. N-acetylcysteine suppresses retinal detachment in an experimental model of proliferative vitreoretinopathy.
Lei H; Velez G; Cui J; Samad A; Maberley D; Matsubara J; Kazlauskas A
Am J Pathol; 2010 Jul; 177(1):132-40. PubMed ID: 20489144
[TBL] [Abstract][Full Text] [Related]
11. Effect of Robo1 on retinal pigment epithelial cells and experimental proliferative vitreoretinopathy.
Huang L; Xu Y; Yu W; Li Y; Chu L; Dong J; Li X
Invest Ophthalmol Vis Sci; 2010 Jun; 51(6):3193-204. PubMed ID: 20071679
[TBL] [Abstract][Full Text] [Related]
12. Pathogenesis of proliferative vitreoretinopathy. Modulation of retinal pigment epithelial cell functions by vitreous and macrophages.
Kirchhof B; Sorgente N
Dev Ophthalmol; 1989; 16():1-53. PubMed ID: 2676632
[TBL] [Abstract][Full Text] [Related]
13. Attenuated glial reaction in experimental proliferative vitreoretinopathy treated with liposomal doxorubicin.
Kuo HK; Chen YH; Wu PC; Wu YC; Huang F; Kuo CW; Lo LH; Shiea J
Invest Ophthalmol Vis Sci; 2012 Jun; 53(6):3167-74. PubMed ID: 22491400
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of retinal pigment epithelial cell-induced tractional retinal detachment by disintegrins, a group of Arg-Gly-Asp-containing peptides from viper venom.
Yang CH; Huang TF; Liu KR; Chen MS; Hung PT
Invest Ophthalmol Vis Sci; 1996 Apr; 37(5):843-54. PubMed ID: 8603869
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of PVR with a tyrosine kinase inhibitor, dasatinib, in the swine.
Umazume K; Liu L; Scott PA; de Castro JP; McDonald K; Kaplan HJ; Tamiya S
Invest Ophthalmol Vis Sci; 2013 Feb; 54(2):1150-9. PubMed ID: 23341014
[TBL] [Abstract][Full Text] [Related]
16. HGF regulation of RPE proliferation in an IL-1beta/retinal hole-induced rabbit model of PVR.
Liou GI; Pakalnis VA; Matragoon S; Samuel S; Behzadian MA; Baker J; Khalil IE; Roon P; Caldwell RB; Hunt RC; Marcus DM
Mol Vis; 2002 Dec; 8():494-501. PubMed ID: 12500176
[TBL] [Abstract][Full Text] [Related]
17. Immunoreactive ET-1 in the vitreous humor and epiretinal membranes of patients with proliferative vitreoretinopathy.
Roldán-Pallarés M; Rollín R; Mediero A; Martínez-Montero JC; Fernández-Cruz A; Bravo-Llata C; Fernández-Durango R
Mol Vis; 2005 Jul; 11():461-71. PubMed ID: 16030497
[TBL] [Abstract][Full Text] [Related]
18. Expression of PDGFRα is a determinant of the PVR potential of ARPE19 cells.
Lei H; Rhéaume MA; Velez G; Mukai S; Kazlauskas A
Invest Ophthalmol Vis Sci; 2011 Aug; 52(9):5016-21. PubMed ID: 21642621
[TBL] [Abstract][Full Text] [Related]
19. Ribozyme to proliferating cell nuclear antigen to treat proliferative vitreoretinopathy.
Mandava N; Blackburn P; Paul DB; Wilson MW; Read SB; Alspaugh E; Tritz R; Barber JR; Robbins JM; Kruse CA
Invest Ophthalmol Vis Sci; 2002 Oct; 43(10):3338-48. PubMed ID: 12356843
[TBL] [Abstract][Full Text] [Related]
20. Inactive Cas9 blocks vitreous-induced expression of Mdm2 and proliferation and survival of retinal pigment epithelial cells.
Chen N; Hu Z; Yang Y; Han H; Lei H
Exp Eye Res; 2019 Sep; 186():107716. PubMed ID: 31278903
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
